PO124 | BLEEDING COMPLICATIONS DURING ANTICOAGULATION WITH DOACS FOR NVAF AND THEIR MOST COMMON RISK FACTORS
Abstract
Background and Aims. CHADS[2]VASc is a score used in the last 15 years to evaluate thrombotic risk in patients with non-valvular atrial fibrillation (NVAF) to address them to anticoagulation with direct oral anticoagulants (DOACs). Yet after years of clinical experience CHADS[2]VASc has been discovered to have also some skill in the identification of bleeding risk. Yet a fine evaluation of its potential role in patients that experienced bleedings during anticoagulation with DOACs is still matter of discussion. Therefore, we analyzed risk factors for bleedings present in two different risk score (i.e. CHADS[2]VASc and RIETE) in 50 inpatients in internal medicine with recent bleeding. The aim of the study is to identify a possible single item that may help to predict possible bleeding during anticoagulation. Methods. We retrospectively analyzed bleeding risk factors in patients hospitalized in internal medicine ongoing DOACs for any reason. We included in our analysis items presents in two different score as RIETE score for anticoagulated patients after a venous thromboembolism and as CHADS2VASC. Furthermore, we included the chronic use of NSAIDs for any reasons. Items evaluated as bleeding risk factors are summarized in table 1. Results. Type of bleeding, previous bleeding, ongoing heart failure, kidney failure, ongoing cancer, female sex, age 40-74 years, age ≥75 years, chronic use (not abuse) of NSAIDs, chronic anaemia, previous venous thrombosis, diabetes, hypertension, other thrombosis in secondary prevention were the items retrospectively analyzed; all of them extracted by two different scores as CHADS[2]VASc and RIETE. Sex distribution and age ≥75 years were equally distributed in the population. Gastrointestinal bleeding was the most common bleeding complication. Hypertension and diabetes were greatly represented in the cohort as far as in the general population. Chronic anaemia, previous bleeding, kidney failure, other thrombotic disease in secondary prevention and heart failure are frequently present in patients with bleedings during anticoagulation with DOACs for NVAF. Conclusions. Phase III clinical trial gave us the chance to understand that cardioembolic stroke prophylaxis with DOACs were not associated to bleedings in particular intracranial hemorrhage. However, in our daily clinical management we noted an increased rate of gastrointestinal bleeding. This difference with phase III clinical trial was probably due to the long-term administration of DOACs in real life compared to the clinical observation of trials (i.e. shorter than 24 months). For these reasons we tried to identify items present in hemorrhagic risk score used in clinical practice hoping to identify a possible major bleeding risk factor. Therefore our cross analysis with items present in RIETE score (a score validated for bleeding risk during anticoagulation) and CHADS[2]VASc (a score used to start anticoagulation for thrombotic risk in NVAF but also associated to bleeding prediction) we find that chronic anaemia, previous bleeding, kidney failure, other thrombotic disease in secondary prevention and heart failure are the most common risk factors in patients hospitalized in internal medicine with bleedings during anticoagulation with DOACs. Further studies on larger cohorts are warranted to confirm our findings, but seems that the complexity of patients is more frequent of a single common risk factor in the bleeding complication during long term anticoagulation for DOACs.
Related
- Outcomes after conversion from mechanical to bioprosthetic valves for anticoagulation-related complications.
- Stroke and Bleeding Risk in Long-Term Care Residents With Atrial Fibrillation Who Discontinue Anticoagulation
- Heavy menstrual bleeding in women with a bleeding disorder of unknown cause: a common symptom impacting daily life functioning
- Prevention and management of bleeding complications in interventional ultrasound: an international expert consensus statement
- Recent advances in anticoagulant-related nephropathy: risk factors, peribiopsy, and therapeutic anticoagulation
BibTeX
@article{femine2026po124,
title = {{PO124 | BLEEDING COMPLICATIONS DURING ANTICOAGULATION WITH DOACS FOR NVAF AND THEIR MOST COMMON RISK FACTORS}},
author = {Augusto Delle Femine},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
month = oct,
url = {https://www.btvb.org/btvb/article/view/940},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - PO124 | BLEEDING COMPLICATIONS DURING ANTICOAGULATION WITH DOACS FOR NVAF AND THEIR MOST COMMON RISK FACTORS
AU - Augusto Delle Femine
PY - 2026
DA - 2026/10/26
JO - Bleeding, Thrombosis and Vascular Biology
UR - https://www.btvb.org/btvb/article/view/940
AB - Background and Aims. CHADS[2]VASc is a score used in the last 15 years to evaluate thrombotic risk in patients with non-valvular atrial fibrillation (NVAF) to address them to anticoagulation with direct oral anticoagulants (DOACs). Yet after years of clinical experience CHADS[2]VASc has been discovered to have also some skill in the identification of bleeding risk. Yet a fine evaluation of its potential role in patients that experienced bleedings during anticoagulation with DOACs is still matter of discussion. Therefore, we analyzed risk factors for bleedings present in two different risk score (i.e. CHADS[2]VASc and RIETE) in 50 inpatients in internal medicine with recent bleeding. The aim of the study is to identify a possible single item that may help to predict possible bleeding during anticoagulation. Methods. We retrospectively analyzed bleeding risk factors in patients hospitalized in internal medicine ongoing DOACs for any reason. We included in our analysis items presents in two different score as RIETE score for anticoagulated patients after a venous thromboembolism and as CHADS2VASC. Furthermore, we included the chronic use of NSAIDs for any reasons. Items evaluated as bleeding risk factors are summarized in table 1. Results. Type of bleeding, previous bleeding, ongoing heart failure, kidney failure, ongoing cancer, female sex, age 40-74 years, age ≥75 years, chronic use (not abuse) of NSAIDs, chronic anaemia, previous venous thrombosis, diabetes, hypertension, other thrombosis in secondary prevention were the items retrospectively analyzed; all of them extracted by two different scores as CHADS[2]VASc and RIETE. Sex distribution and age ≥75 years were equally distributed in the population. Gastrointestinal bleeding was the most common bleeding complication. Hypertension and diabetes were greatly represented in the cohort as far as in the general population. Chronic anaemia, previous bleeding, kidney failure, other thrombotic disease in secondary prevention and heart failure are frequently present in patients with bleedings during anticoagulation with DOACs for NVAF. Conclusions. Phase III clinical trial gave us the chance to understand that cardioembolic stroke prophylaxis with DOACs were not associated to bleedings in particular intracranial hemorrhage. However, in our daily clinical management we noted an increased rate of gastrointestinal bleeding. This difference with phase III clinical trial was probably due to the long-term administration of DOACs in real life compared to the clinical observation of trials (i.e. shorter than 24 months). For these reasons we tried to identify items present in hemorrhagic risk score used in clinical practice hoping to identify a possible major bleeding risk factor. Therefore our cross analysis with items present in RIETE score (a score validated for bleeding risk during anticoagulation) and CHADS[2]VASc (a score used to start anticoagulation for thrombotic risk in NVAF but also associated to bleeding prediction) we find that chronic anaemia, previous bleeding, kidney failure, other thrombotic disease in secondary prevention and heart failure are the most common risk factors in patients hospitalized in internal medicine with bleedings during anticoagulation with DOACs. Further studies on larger cohorts are warranted to confirm our findings, but seems that the complexity of patients is more frequent of a single common risk factor in the bleeding complication during long term anticoagulation for DOACs.
SN - 2785-5309
ER -